Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aflibercept FER (ATC-Code nach WHO: S01LA05; ausgenommen 114,3 mg/ml)

The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance Aflibercept as an injection solution in a pre-filled syringe (ATC code according to WHO: S01LA05; excluding 114.3 mg/ml). The contract is concluded within the framework of an open house model, i.e. a contract is available to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations will not be conducted and there will be no (supply) exclusivity. It is noted that the quantity to be procured is unknown, as it depends on demand and the development of the number of insured persons, the prescribing behaviour of doctors, and the dispensing and stocking behaviour of public pharmacies. Minimum procurement quantities will therefore not be guaranteed. Interested pharmaceutical companies can download the participation documents from the project room of the German Tender Portal (DTVP). For this purpose, an application for access to the project room is initially required. After activation by the contracting entity, the participation documents can then be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the discount agreement and the discounts mentioned therein. Any full or partial disclosure or provision of contents of the participation documents to or for third parties requires the prior written consent of the contracting entity. If participation is waived, all documents must be destroyed immediately in accordance with data protection regulations. The documents to be submitted are set out in the documents "Cover Letter" and "Explanation of the Contract Terms" stored in the project room. Communication, including the transmission of the participation documents, takes place electronically via the tender portal DTVP; details can be found in the aforementioned documents. Any contradictory information in the contract notice is due to technical reasons and is not binding. Participation applications can be submitted for the first time by 2 December 2026. All further submission deadlines can be found in the attachment "Submission Deadlines" stored in the project room. If the deadline for submission falls on a Saturday, Sunday or a nationwide public holiday, the following working day shall take its place. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The discount agreement ends, regardless of the date of the contract conclusion, at the latest on 31 December 2027. The contracting entity reserves the right to terminate the open house procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the already concluded discount agreements will end in accordance with the contractual provisions. According to the contracting entity's experience, exclusive discount agreements generally come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.